Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$201.7MCash on Hand
23.3mo Cash Runway
Follow CATX by emailGet an email when CATX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CATX, unsubscribe in one click. Privacy
📣 What CATX Says Is Next
1Q 2027 · “We are targeting an end-of-Phase 2 meeting with the FDA in 1Q 2027.”
Company press release, Nov 9, 2026 · SEC filing
in 2027 · “FDA feedback and completion of the necessary clinical, regulatory, and operational activities are expected to enable initiation of the Phase 3 study in 2027.” NANETS presentation highlights rationale for enrichment strategy Across Cohorts 1-3 of the ongoing Phase 1/2 dose finding study, 68 patients received at least one treatment of bamzireotide.”
Company press release, Nov 6, 2026 · SEC filing
first quarter of 2027 · ““We are incorporating these findings as a potential enrichment strategy into ongoing discussions with regulators on the design of a registration enabling study, and are targeting an end-of-Phase 2 meeting in the first quarter of 2027.”
Company press release, Nov 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Earnings Reported Q3 2026 results with R&D expenses of $26.1 million and a net loss of $32.4 million, or $0.27 per share, and about $202 million in cash and investments, sufficient into 2028. Also announced FDA Fast Track designation for PSV359 in solitary fibrous tumors and a Merck clinical trial collaboration. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 6, 2026 ·
Clinical trial Reported incremental Phase 1/2a data for VMT-α-NET at NANETS 2026: among 57 GEP-NET patients with all target lesions SSTR2-positive, PFS was 75% at 18 months, disease control 95%, and objective response 39%. Targeting an end-of-Phase 2 meeting in 1Q 2027. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Clinical trial Perspective Therapeutics reported updated interim monotherapy data for lapemelanotide zapixetar (VMT01) in advanced melanoma at SITC: 20 patients, 75% disease control rate at the 3.0 mCi dose, two confirmed responders, and no dose-limiting toxicities. Form 8-K · SEC filing · Press release
Oct 23, 2026 ·
Clinical trial Interim Phase 1/2a data for [212Pb]VMT-α-NET in SSTR2-positive NETs showed ORR of 33% in Cohort 2 (n=46) and 50% in Cohort 3 (n=20), DCR of 89% and 95%, 72% PFS at 18 months, and no DLTs. Form 8-K · SEC filing · Press release
Oct 8, 2026 ·
Regulatory FDA granted Fast Track Designation for PSV359, an FAP-targeted alpha-particle therapy, for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. The drug is in an ongoing Phase 1/2a study for advanced FAP-positive solid tumors. Form 8-K · SEC filing · Press release
Oct 1, 2026 ·
Perspective Therapeutics updated its corporate presentation, filed as Exhibit 99.1, covering its radiopharmaceutical pipeline including VMT-α-NET, VMT01, PSV359 and CCK2R81 targeting solid tumors. Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
Deal Perspective Therapeutics announced a clinical trial collaboration with Merck to evaluate [212Pb]PSV359 with Keytruda (pembrolizumab) in FAP-α positive solid tumors. Merck is providing pembrolizumab at no cost, and the Company sponsors the Phase 1/2a study. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 1/2 · Recruiting · MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma Registry primary completion date, not a results date
Jan 2028 · Phase 1/2 · Recruiting · Lead-212 PSV359 Therapy for Patients With Solid Tumors Registry primary completion date, not a results date
Nov 2029 · Phase 1/2 · Recruiting · Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not CATX's own candidates): Nivolumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CATX holds $201.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $26M/quarter from operations,
an estimated runway of 23.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:48 · Elevated
Cash runway 23 months +8
ATM program on file since Feb 2026 +15
Shelf registration (S-3ASR, May 2024) +10
Company says cash lasts into 2028 -5We believe our cash, cash equivalents and short-term investments will be sufficient to fund our current planned clinical milestones and operational investments for at least the next 12 months from the date the condensed consolidated financial statements in this report were issued and into 2028.10-Q, Nov 2026
Share count 120,758,815 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CATX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CATX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.